Newly discovered pathway fuels production of cancer-driving proteins
Stanford researchers have identified a protein translation pathway involving the METTL13 enzyme that drives cancer growth and drug resistance.
13 trends tracked about this subject — the full history, oldest to newest below.
Stanford researchers have identified a protein translation pathway involving the METTL13 enzyme that drives cancer growth and drug resistance.
An experimental mRNA vaccine targeting KRAS mutations triggered immune responses in 99% of pancreatic cancer patients in recent Phase 2 study results.
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
Recent studies detail an mRNA immunotherapy strategy that reportedly leads to pancreatic cancer disappearing in mice.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A mutant KRAS vaccine yields early positive results in its first human clinical trial for high-risk pancreatic cancer patients.
A Johns Hopkins-developed KRAS vaccine has demonstrated safety and durable immune responses in a trial focused on preventing pancreatic cancer in high-risk individuals.
A new pill-based treatment targeting KRAS-mutated pancreatic cancer is generating expert excitement and hope for patient longevity.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.